Not Tagged
amgen
['biomarker', 'nsclc', 'lung', 'sclc', 'amgen']
roughly half of all patients with non-small cell lung cancer (#nsclc) harbor a targetable driver mutation responsible for initiating cancer &amp; driving its growth. for these patients, targeted therapy enabled by #biomarker testing may lead to improved outcomes.
#aacr23 #medtwitter
Advancing All Angles of Care. Tweets intended for U.S. audience. See our Community Guidelines: https://t.co/WUbqtYa6KT.